Identification of the 7-lncRNA Signature as a Prognostic Biomarker for Acute Myeloid Leukemia

Liu, Chunyu; Guo, Huihui; Li, Haixia; Liang, Ying; Tang, Cong; Chen, Nannan

doi:10.1155/2021/8223216

Cited by 4 publications

(4 citation statements)

References 34 publications

(37 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Interestingly, none of these lncRNA have defined functions in cancer or AML, thereby highlighting the value of lncRNAs as biomarkers independent of their mechanism (C. Y. Liu et al, 2021).…”

Section: Biomarkersmentioning

confidence: 99%

“…They found that their 7‐lncRNA signature (LINC00461, RP11—309 M23.1, AC016735.2, RP11—61I13.3, KIAA0087, RORB—AS1, AC012354.6) was able to accurately predict patient outcome with patients with a high “risk score” having poor OS compared to the low‐risk score cohort. Interestingly, none of these lncRNA have defined functions in cancer or AML, thereby highlighting the value of lncRNAs as biomarkers independent of their mechanism (C. Y. Liu et al, 2021 ).…”

Section: Lncrna Function In Cancer and Amlmentioning

confidence: 99%

See 1 more Smart Citation

The tip of the iceberg—The roles of long noncoding RNAs in acute myeloid leukemia

Connerty

Lock

2023

WIREs RNA

View full text Add to dashboard Cite

Long noncoding RNAs (lncRNAs) are traditionally defined as RNA transcripts longer than 200 nucleotides that have no protein coding potential. LncRNAs have been identified to be dysregulated in various types of cancer, including the deadly hematopoietic cancer—acute myeloid leukemia (AML). Currently, survival rates for AML have reached a plateau necessitating new therapeutic targets and biomarkers to improve treatment options and survival from the disease. Therefore, the identification of lncRNAs as novel biomarkers and therapeutic targets for AML has major benefits. In this review, we assess the key studies which have recently identified lncRNAs as important molecules in AML and summarize the current knowledge of lncRNAs in AML. We delve into examples of the specific roles of lncRNA action in AML such as driving proliferation, differentiation block and therapy resistance as well as their function as tumor suppressors and utility as biomarkers.This article is categorized under: RNA in Disease and Development > RNA in Disease

show abstract

Section: Biomarkersmentioning

confidence: 99%

Section: Lncrna Function In Cancer and Amlmentioning

confidence: 99%

The tip of the iceberg—The roles of long noncoding RNAs in acute myeloid leukemia

Connerty

Lock

2023

WIREs RNA

View full text Add to dashboard Cite

show abstract

“…Emerging evidence has identified that various ir-lncRNAs have significant associations with the cancer cell response to anti-PD-1 immunotherapy in multiple tumors [ 6 , 7 ]. Some lncRNA signatures have been identified in AML, and their expression was associated with the survival of patients with AML [ 8 – 10 ]. Still, all these prognostic models were established based on the expression of lncRNAs, which limited the clinical application.…”

Section: Introductionmentioning

confidence: 99%

Immune-related lncRNAs pairs prognostic score model for prediction of survival in acute myeloid leukemia patients

Liang,

Li,

Fan

et al. 2023

Clin Exp Med

View full text Add to dashboard Cite

Acute myeloid leukemia (AML) is one of the most common malignant and aggressive hematologic tumors, and risk stratification is indispensable to ensure proper treatment. But immune-related long noncoding RNAs (ir-lncRNAs) pairs prognostic risk models used to stratify AML have yet to be reported. In this study, we established a prognostic risk model based on eight ir-lncRNAs pairs using LASSO-penalized Cox regression analysis and successfully validated the model in an independent cohort. According to risk scores, patients were divided into a high-risk group and a low-risk group. High-risk patients presented more tumor mutation frequency and higher expression of human leukocyte antigen (HLA)-related genes and immune checkpoint molecules. Gene Set Enrichment Analysis (GSEA) indicated that the transforming growth factors β (TGFβ) pathway was activated in the high-risk group; meanwhile, we found that TGFβ1 mRNA levels were significantly elevated in AML patients and correlated with poor prognosis, which is closely related to drug resistance. Consistently, in vitro studies found that exogenous TGFβ1 can protect AML cells from chemotherapy-induced apoptosis. Collectively, we developed an ir-lncRNA prognostic model that helps predict the prognosis of AML patients and provides valuable information about their response to immune checkpoint inhibitors, and we found that increased TGFβ1 levels resulting in chemoresistance may be one of the leading causes of treatment failure in high-risk AML patients.

show abstract

“…Serum LINC00899 was predicted to be a potential and useful noninvasive biomarker for the early clinical detection and prognosis of AML (Wang et al, 2018). Interestingly, several lncRNA-based integrated models have been developed for the stratification of AML patients (Liu et al, 2021;Zhu et al, 2023). Recently, an integrated prognostic signature encompassing five immunerelated protein-coding genes and an immune-related lncRNA has been successfully constructed to predict the survival and stratification of AML patients (Zhao et al, 2022).…”

Section: Introductionmentioning

confidence: 99%

Computational analysis of heat shock proteins and ferroptosis-associated lncRNAs to predict prognosis in acute myeloid leukemia patients

Ge,

Wang,

Sharma

et al. 2023

Front. Genet.

View full text Add to dashboard Cite

Owing to their functional diversity in many cancers, long noncoding RNAs (lncRNAs) are receiving special attention. LncRNAs not only function as oncogenes or tumor suppressors by participating in various signaling pathways but also serve as predictive markers for various types of cancer, including acute myeloid leukemia (AML). Considering this, we investigated lncRNAs that may act as a mediator between two processes, i.e., heat shock proteins and ferroptosis, which appear to be closely related in tumorigenesis. Using a comprehensive bioinformatics approach, we identified four lncRNAs (AL138716.1, AC000120.1, AC004947.1, and LINC01547) with prognostic value in AML patients. Of interest, two of them (AC000120.1 and LINC01547) have already been reported to be AML-related, and AC004947.1 is considered to have oncogenic potential. In particular, the signature obtained showed a lower survival probability with high-risk patients, and vice versa. To our knowledge, this is the first predictive model of lncRNA that may correlate with the processes of heat shock proteins and ferroptosis in AML. Nevertheless, validation using patient samples is warranted.

show abstract

Identification of the 7-lncRNA Signature as a Prognostic Biomarker for Acute Myeloid Leukemia

Cited by 4 publications

References 34 publications

The tip of the iceberg—The roles of long noncoding RNAs in acute myeloid leukemia

The tip of the iceberg—The roles of long noncoding RNAs in acute myeloid leukemia

Immune-related lncRNAs pairs prognostic score model for prediction of survival in acute myeloid leukemia patients

Computational analysis of heat shock proteins and ferroptosis-associated lncRNAs to predict prognosis in acute myeloid leukemia patients

Contact Info

Product

Resources

About